Celularity Inc
CELU- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001752828
No open-market purchases or sales by Celularity Inc insiders were filed in the last 90 days; 39 institutions reported holding it in 13F filings for Q2 2026, worth $2.44M in total; no superinvestor holds it.
Open-market trades, last 90 days
Open-market purchases (P) and sales (S) by Celularity Inc insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.
- Open-market buys
- 0 filings
- Open-market sells
- 0 filings
- Insiders trading
- 0
- Net value
- $0
- Purchases minus sales
Insider roster
Directors, officers and 10% owners who have filed a Form 4 for Celularity Inc, current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.
| Name | Title | Last reported holding | Last filing | Filings, past year |
|---|---|---|---|---|
| Philip & Daniele Barach Family Trust | 10% Owner | – | Sep 25, 2026 | 2 |
| Barach Daniele Wolf | 10% Owner | – | Sep 25, 2026 | 2 |
| Barach Philip Alan | Director, 10% Owner | – | Sep 25, 2026 | 2 |
| Hariri Robert J | Chief Executive Officer | 2,853,553 | Apr 15, 2026 | 1 |
| Haines John R | Senior Exec Vice President | 30,179 | Apr 15, 2026 | 1 |
| Brigido Stephen | Pres., Functional Regeneration | 9,474 | Apr 15, 2026 | 1 |
| Diamandis Peter | Director | 394,150 | Jan 15, 2026 | 4 |
| Parks Diane L. | Director | 520,021 | Jan 15, 2026 | 4 |
| Ling Geoffrey M.D. | Director | 256,026 | Jan 15, 2026 | 4 |
| LeVien Vincent | Director | 153,847 | Jan 15, 2026 | 3 |
| Lim Kok Thay | 10% Owner | 6,335,630Indirect | Jul 28, 2025 | 0 |
| Genting Berhad | 10% Owner | 6,335,630Indirect | Jul 28, 2025 | 0 |
| Resorts World Inc Pte. Ltd. | 10% Owner | – | Jul 28, 2025 | 0 |
| Beers David C | Chief Financial Officer | 18,201 | Apr 15, 2025 | 0 |
| Dragasac Ltd | 10% Owner | 6,335,630Indirect | Jan 28, 2025 | 0 |
| Berman Richard J | Director | 67,416 | Jan 6, 2025 | 0 |
| Kehler Dean C | Director | 303,482 | Jan 6, 2025 | 0 |
| Fletcher Kyle | See Remarks | 21,085 | Apr 16, 2024 | 0 |
| Kilcoyne Adrian | Chief Medical Officer | 1,122,238 | Feb 21, 2024 | 0 |
| Sorrento Therapeutics, Inc. | 10% Owner | 5,050,427 | Oct 5, 2023 | 0 |
| Sculley John | Director | 1,004,660 | Jun 16, 2023 | 0 |
| Mazur Marc | Director | 236,066 | Jun 16, 2023 | 0 |
| Smith Robin L | Director | 236,066 | Jun 16, 2023 | 0 |
| Von Eschenbach Andrew C. | Director | 336,066 | Jun 16, 2023 | 0 |
| Glover Bradley | See Remarks | 351,192 | Apr 17, 2023 | 0 |
| Jones Anne | Chief Business Officer | 49,154 | Nov 18, 2022 | 0 |
| Dunn Keary | See Remarks | 16,405 | Apr 28, 2022 | 0 |
| Starr International Co Inc | 10% Owner | 15,281,389Indirect | Mar 15, 2022 | 0 |
| Starr International Investments Ltd. | 10% Owner | 15,281,389Indirect | Mar 15, 2022 | 0 |
| Pecora Andrew L | President | – | Sep 17, 2021 | 0 |
| Mirakhur Beloo | EVP, Clinical Development | – | Sep 15, 2021 | 0 |
| Bloom Jay R | Director | 100,000Indirect | Sep 13, 2021 | 0 |
| GX Sponsor LLC | 10% Owner | 100,000 | Jul 20, 2021 | 0 |
Insider trades
Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Jan 17, 2024 (view filing)5:22 PM ET | Jan 12 | 5 days | Lim Kok Thay and 2 others10% Owner | PPurchaseClass A Common Stock | +21.4M | $0.249 | +$5.33M | +71.2%51.5M after | |
| Jan 17, 2024 (view filing)5:22 PM ET | Jan 12 | 5 days | Lim Kok Thay and 2 others10% Owner | PPurchaseClass A Common Stock | +21.9M | $0.125 | +$2.73M | –16.5M after | Derivative2 lots |
| Oct 10, 2023 (view filing)9:48 PM ET | Sep 29-Oct 5 | 11 daysLate | Hariri Robert JChief Executive Officer | PPurchaseClass A Common Stock | +18.4M | $0.162 | +$2.98M | +181.5%28.6M after | 3 lots |
| Oct 5, 2023 (view filing) | Sep 29-Oct 5 | 6 daysLate | Sorrento Therapeutics, Inc.10% Owner | SSaleClass A Common Stock | −15.4M | – | – | −75.3%5.05M after | 2 lots |
| Jun 22, 2023 (view filing)4:32 PM ET | Jun 20 | 2 days | Genting Berhad10% Owner | PPurchaseClass A Common Stock | +3.00M | $0.125 | +$375.0K | –3.00M after | Derivative |
| Nov 30, 2022 (view filing) | Nov 30 | Same day | Hariri Robert JChief Executive Officer | PPurchaseClass A Common Stock | +10.0K | $1.72 | +$17.2K | +0.1%8.07M after | |
| Nov 29, 2022 (view filing) | Nov 29 | Same day | Hariri Robert JChief Executive Officer | PPurchaseClass A Common Stock | +40.0K | $1.71 | +$68.4K | +0.5%8.06M after | |
| Nov 28, 2022 (view filing) | Nov 28 | Same day | Hariri Robert JChief Executive Officer | PPurchaseClass A Common Stock | +40.0K | $1.74 | +$69.6K | +0.5%8.02M after |